Symptom-driven Referral for Evaluation of Chronic Thromboembolic Disease or Pulmonary Hypertension in Patients With Previous Acute Pulmonary Embolism

Sponsor
University of Aarhus (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT03729492
Collaborator
Hospitalsenheden Vest (Other)
100
1
45

Study Details

Study Description

Brief Summary

Aim: To investigate if a symptom driven referral for chronic thrombosis in the lungs after acute pulmonary embolism is better than the current approach.

Background: A number of patients with chronic thrombosis in the lungs after acute pulmonary embolism have dyspnea and reduced functional capacity without elevated pulmonary arterial pressure at rest (CTED). However, current guidelines for follow-up after acute pulmonary embolism will miss all patients with CTED, as referral for further examination is based on elevated pulmonary arterial pressure on echocardiography. Thus, the prevalence of CTED is unknown. The hypothesis is, that a symptom-driven referral of patients with previous acute pulmonary embolism is more sensitive in diagnosing CTED than the current approach.

Methods and materials: Patients diagnosed with acute pulmonary embolism in Region Midt (approx. 350 per year) will be screened for non-recovery or persistent pulmonary embolism related symptoms during their 3-6 months follow up at their local outpatient clinic. If the patient has persistent symptoms they will be referred to a scintigraphy. If CTED is suspected from the scintigraphy, the patient will be referred for full CTED work-up. The investigators expect to screen 300 patients for persistent symptoms with an expected study time of 3 years.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: CTEPH/CTED work-up
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
100 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Diagnostic
Official Title:
Symptom-driven Referral for Evaluation of Chronic Thromboembolic Disease or Pulmonary Hypertension in Patients With Previous Acute Pulmonary Embolism
Anticipated Study Start Date :
Feb 1, 2019
Anticipated Primary Completion Date :
Nov 1, 2022
Anticipated Study Completion Date :
Nov 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Other: CTEPH/CTED work-up

Diagnostic Test: CTEPH/CTED work-up
Patients diagnosed with acute pulmonary embolism (PE) in Region Midt (approx. 350 per year) will be screened for non-recovery or persistent PE related symptoms during their 3-6 months follow up at their local outpatient clinic. If the patient has persistent symptoms they will be referred to a V/Q-scan. If a V/Q mismatch is present, the patient will be referred to a full work-up for CTEPH/CTED.

Outcome Measures

Primary Outcome Measures

  1. Prevalence of CTED [3 years]

Secondary Outcome Measures

  1. Diagnostic accuracy of dual energy CT perfusion and pulmonary angiography. [3 years]

    Sensibility, specificity, positive predictive value and negative predictive value

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 79 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Acute PE diagnosed by CT or V/Q-scan within the last year.

  • Non-recovery or persistent PE related symptoms assessed by a MRC breathlessness score or WHO functional class.

  • Age >= 18 and < 80

Exclusion Criteria:
  • Contraindications or unable to perform 6 minutes walk distance (6MWD) and/or cardiopulmonary exercise test.

  • Contraindications to CT pulmonary angiography.

  • Congestive heart failure (LVEF <40%).

  • COPD or restrictive lung disease, severe or worse (FEV1 <50% and >=1 exacerbation causing hospital admission per year (GOLD grade 3 and 4 class C and D)).

  • Lactating or pregnant.

  • Unable or unwilling to provide written informed consent.

  • Paroxysmal or persistent atrial fibrillation.

  • Other known cause of PE related symptoms.

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • University of Aarhus
  • Hospitalsenheden Vest

Investigators

  • Study Chair: Asger Andersen, MD, PhD, Aarhus University Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University of Aarhus
ClinicalTrials.gov Identifier:
NCT03729492
Other Study ID Numbers:
  • CTEPH
First Posted:
Nov 2, 2018
Last Update Posted:
Nov 2, 2018
Last Verified:
Oct 1, 2018
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 2, 2018